XII Medical, a clinical-stage medical technology company focused on developing neuromodulation therapies for obstructive sleep apnea (OSA), has closed a $45 million Series B financing round. The funding was led by Omega Funds and included participation from Intuitive Ventures, Cleveland Clinic, Ajax Health, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, and an undisclosed strategic investor. The capital will be used to advance their innovative, patient-centric OSA treatment technology designed to improve the quality of life for millions. XII Medical’s platform technology simplifies treatment, expands access, and improves patient outcomes. Key investors emphasize the potential for XII Medical’s neuromodulation therapy to address compliance issues and offer a minimally invasive solution for OSA patients.
Healthcare, Medical Technology, Venture Capital,United States
https://www.prnewswire.com/news-releases/xii-medical-raises-45-million-in-series-b-financing-to-advance-best-in-class-neuromodulation-therapy-for-obstructive-sleep-apnea-302227451.html?tc=eml_cleartime